menu search

Verona pharma to present additional analyses of positive phase 3 enhance studies in copd at chest 2023

PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine,  an investigational, novel, se...

October 3, 2023, 2:00 am

Theravance: positive findings boost ampreloxetine development

Theravance Biopharma has a diversified portfolio in the healthcare sector, with the potential for high returns and risk mitigation. The company's fina...

September 9, 2023, 11:49 am

Theravance biopharma: yupelri numbers don't substantiate 9x forward sales, rate hold

Theravance Biopharma has pushed into congestion in 2023, backing and filling throughout the year. Its YUPELRI label offers targeted bronchodilation fo...

September 8, 2023, 10:12 am

Verona pharma to present additional analysis of phase 3 enhance-1 study in copd at ers international congress 2023

Substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PD...

September 6, 2023, 2:00 am

Verona pharma: de-risked copd biotech play, approval likely coming soon

Verona Pharma has submitted a New Drug Application (NDA) for ensifentrine, a potential treatment for copd...

September 4, 2023, 11:45 pm

Verona pharma: financial health and copd market impact 2024

Verona Pharma is seeking FDA approval for its copd treatment, ensifentrine, in 2024. The company has a ...

August 24, 2023, 4:05 pm

Honeywell (hon), recipharm unite to develop near-zero gwp pmdis

The deal between Honeywell (HON) and Recipharm allows them to offer low greenhouse gas pMDIs to patients suffering from ...

August 18, 2023, 2:04 pm

Verona pharma: targeting the large copd market

Verona Pharma plc is a London-based biopharma company focused on developing respiratory disease treatments. The company recently submitted a NDA for i...

August 8, 2023, 4:44 pm

Ipo update: apogee therapeutics proposes terms for $250 million ipo

Apogee Therapeutics, Inc. has filed proposed terms for a $250 million IPO. The firm is developing drug treatment candidates for atopic dermatitis, ...

July 10, 2023, 5:33 pm

Apogee therapeutics sets ipo terms, to be valued at up to $774.5 mln

Apogee Therapeutics Inc. APGE, has set terms for its initial public offering, as the Massachusetts-based biotechnology company developing treatments f...

July 10, 2023, 6:28 am

Wellinks and highmark blue cross blue shield delaware partner to reduce access barriers through virtual copd care

This Partnership Will Enable Members in Delaware to Receive Integrated Care for Chronic Obstructive Pulmonary Disease NEW HAVEN, Conn., June 30, 2023 ...

June 30, 2023, 2:00 pm

Verona pharma: poised for a breakthrough in copd treatment amidst favorable financial position

Verona Pharma, a clinical-stage biopharmaceutical company, is making strides with its novel copd treatm...

May 28, 2023, 9:08 am

Pneumatic nebulizers market set to surpass usd 1.3 billion by 2031 with 7.3% of cagr | global analysis by transparency market research

Respiratory failure caused by acute chronic obstructive pulmonary disease (copd) can be deadly, which i...

May 26, 2023, 4:30 pm

Dupixent® (dupilumab) late-breaking phase 3 copd results presented at ats and simultaneously published in the new england journal of medicine

Dupixent is the first and only investigational biologic for copd that has demonstrated a significant re...

May 21, 2023, 6:18 pm

Verona pharma: revolutionizing copd with first triple mechanism inhaled drug

Verona Pharma plc's Ensifentrine is the first drug that combines bronchodilation and anti-inflammatory effects in ...

May 18, 2023, 6:51 pm

Increasing incidence of respiratory diseases drives the growth of single-use bronchoscopes market to us$ 3.26 billion by 2033, says persistence market research

Growing Demand for Minimally Invasive Diagnostic Services and Low-cost Endoscopy Alternatives Increasing Use of Single-use Bronchoscopes New York, May...

May 9, 2023, 1:55 pm

Verona pharma to present expanded analyses of positive phase 3 enhance studies in copd in multiple presentations at ats 2023

12 Abstracts and one Symposium further support potential of ensifentrine, a first-in-class, selective, dual inhibitor of PDE3 and PDE4...

May 2, 2023, 2:00 am

Regeneron: new highs following dupixent's copd data

Shares of Regeneron jumped to new all-time highs following the successful phase 3 results of Dupixent in copd<...

April 13, 2023, 6:12 am

Is this pharma duo on the brink of another billion-dollar opportunity?

Dupixent's recent clinical data suggest it is a viable treatment option for adult patients with chronic obstructive pulmonary disease (...

March 30, 2023, 5:48 am

Sanofi, regeneron shares pop on big news about copd treatment

Shares of Sanofi (NASDAQ: SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) finished with a gain of 9.6...

March 27, 2023, 1:26 pm


Search within

Pages Search Results: